Summary
The episode works through four questions that students commonly find difficult in the lesson on cannabis, psychedelics and new psychoactive substances. Sarah and Kiffer separate the amount of THC in a product from its effect, drawing on a 2014 Dutch study of titration and on Canada's legal THC limits, and then read the odds ratios and attributable fractions of the EU-GEI study, including why fractions for overlapping exposures cannot be added and how sensitive they are to the assumption of causality. They use the receptor-share model to distinguish affinity from efficacy in synthetic cannabinoids, discuss what control status and early warning data can tell public health, and show with a hypothetical sample how the way cases are found can inflate estimates of ketamine-associated bladder symptoms. The hosts then disagree about how far Nutt and colleagues' 2007 expert harm ratings should inform drug schedules, and agree to ask who did the rating, when, for which forms of use and with what weights.